Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frenken

Showing results (31-40 of 347) with videos related to

Pageof 35
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1989
Dimethylation of the activator ICI 169,369 results in a high-affinity partial deactivator, ICI 170,809, of the arterial 5-hydroxytryptamine2 receptor systemM Frenken, A J Kaumann
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 1, 1988
Effects of tryptamine mediated through 2 states of the 5-HT2 receptor in calf coronary arteryM Frenken, A J Kaumann
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 1, 1987
Allosteric properties of the 5-HT2 receptor system of the rat tail artery. Ritanserin and methysergide are not competitive 5-HT2 receptor antagonists but allosteric modulatorsM Frenken, A J Kaumann
Obesity Facts|October 27, 2011
Metabolic intestinal bypass surgery for type 2 diabetes in patients with a BMI <35 kg/m2: comparative analysis of 16 patients undergoing either BPD, BPD-DS, or RYGBMichael Frenken, Eun-Young Cho
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 1, 1987
Interconversion into a low active state protects vascular 5-HT2-receptors against irreversible antagonism by phenoxybenzamineM Frenken, A J Kaumann
Physical Review Letters|January 14, 1985
Observation of surface meltingFrenken, van der Veen JF
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1988
ICI 169,369 is both a competitive antagonist and an allosteric activator of the arterial 5-hydroxytryptamine2 receptor systemA J Kaumann, M Frenken
Physical Review Letters|October 4, 2000
Anomalous shape and decay of islands on Au(110)Rost, van Gastel R, Frenken
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 1, 1985
A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Allosteric regulation of 5-HT2-receptorsA J Kaumann, M Frenken
Contributions to Nephrology|January 1, 1990
Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?R A Koene, L A Frenken
Pageof 35

Showing results (31-40 of 347) with videos related to

Sort By:
Pageof 35
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1989
Dimethylation of the activator ICI 169,369 results in a high-affinity partial deactivator, ICI 170,809, of the arterial 5-hydroxytryptamine2 receptor systemM Frenken, A J Kaumann
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 1, 1988
Effects of tryptamine mediated through 2 states of the 5-HT2 receptor in calf coronary arteryM Frenken, A J Kaumann
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 1, 1987
Allosteric properties of the 5-HT2 receptor system of the rat tail artery. Ritanserin and methysergide are not competitive 5-HT2 receptor antagonists but allosteric modulatorsM Frenken, A J Kaumann
Obesity Facts|October 27, 2011
Metabolic intestinal bypass surgery for type 2 diabetes in patients with a BMI <35 kg/m2: comparative analysis of 16 patients undergoing either BPD, BPD-DS, or RYGBMichael Frenken, Eun-Young Cho
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 1, 1987
Interconversion into a low active state protects vascular 5-HT2-receptors against irreversible antagonism by phenoxybenzamineM Frenken, A J Kaumann
Physical Review Letters|January 14, 1985
Observation of surface meltingFrenken, van der Veen JF
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1988
ICI 169,369 is both a competitive antagonist and an allosteric activator of the arterial 5-hydroxytryptamine2 receptor systemA J Kaumann, M Frenken
Physical Review Letters|October 4, 2000
Anomalous shape and decay of islands on Au(110)Rost, van Gastel R, Frenken
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 1, 1985
A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Allosteric regulation of 5-HT2-receptorsA J Kaumann, M Frenken
Contributions to Nephrology|January 1, 1990
Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?R A Koene, L A Frenken
Pageof 35